HER2 Low Breast Cancer

The Destiny lungo for is still a little bit of time away. And this is an international trial that we're doing across North America in Latin America, Asia and Europe. So that's what it takes to accrue to a study of this size. This is in a rare tumor population, arguably not commonly tested. Most oncology practices do not test for her too,. unless it's part of a broad NGS panel, which takes time to get results.